How CAR T cells recognize cancer
CAR T-cell therapy equips T cells with a receptor that recognizes a particular target. Common autologous products begin with cells collected from the patient, which are engineered and expanded before being returned. Unlike an ordinary drug infusion, the living cells may multiply and remain active in the body.
A useful assessment therefore starts with the exact diagnosis, the proposed product and target, and previous treatment. “Having CAR T” is not yet a complete treatment plan.
Who may be a candidate
CAR T has established roles in selected blood cancers. Solid-tumor applications need product-specific assessment. This map explains the differences; it is not a universal list of approved indications.
| Clinical setting | Target or product | What must be checked |
|---|---|---|
| Selected B-cell leukemias and lymphomas | CD19-directed CAR T | Subtype, age, relapse or refractory status, prior treatment and the local product label. |
| Relapsed or refractory multiple myeloma | BCMA-directed CAR T | Previous drug exposure, resistance and treatment lines; requirements differ by product. |
| Selected advanced gastric or gastroesophageal junction cancer | CLDN18.2-directed satri-cel (CT041) | The Chinese approval has biomarker, HER2 and prior-treatment requirements; it does not cover all gastric cancers. |
| Other solid tumors or new CAR T designs | Defined by the study | Many applications remain investigational. A target alone does not establish an approved option. |
Referral need not wait until every treatment has failed
Some products are used earlier in relapse. For example, the US CARVYKTI indication includes adults with myeloma after at least one prior line containing a proteasome inhibitor and an immunomodulatory drug, who are refractory to lenalidomide. This illustrates why referral timing is product-specific; it is not the label for every CAR T therapy.
Eligibility and readiness are separate questions
The team also considers disease tempo, infection, organ function, blood counts and the feasibility of collection and manufacturing. Age is only one factor. Caregiver support, nearby accommodation and a route back to urgent specialist care also matter.
Global treatment frontiers
Solid tumors bring challenges beyond those addressed in blood cancers: uneven target expression, targets shared with healthy tissue and a suppressive tumor environment. Multi-target, allogeneic and other engineered approaches are being studied, but each needs its own clinical evidence.
In June 2026, China approved satri-cel (CT041) for selected CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior treatment lines have failed. The manufacturer’s approval announcement identifies it as the first CAR T product approved for solid tumors. Individual eligibility still requires the local prescribing information.
A shared target does not mean a shared treatment role. The US-approved CLDN18.2 antibody zolbetuximab is given with chemotherapy in the first-line setting, whereas CT041 has a later-line cell-therapy indication. Different lines, testing requirements and studies prevent a simple cross-trial ranking or substitution.
From collection to infusion
Autologous CAR T is a treatment pathway, not a one-day procedure. Manufacturing commonly takes weeks; scheduling, cell quality and changes in health can alter the plan.
Collection and manufacturing
Apheresis collects T cells for engineering, expansion and quality checks. Collection does not guarantee infusion. Ask what happens if manufacturing is delayed or the cells do not meet release requirements.
Bridging treatment controls disease while waiting
Some patients need treatment during manufacturing. The choice depends on disease behavior, previous response and the planned cell therapy. Do not stop existing treatment yourself while awaiting collection.
Lymphodepletion prepares for the cells
Pre-infusion chemotherapy reduces some existing lymphocytes to support CAR T-cell expansion. Its purpose differs from bridging therapy; the two are not interchangeable.
Infusion and early monitoring
Cells are infused intravenously. Inpatient or outpatient care depends on the product, patient and center. Close monitoring follows, even if the infusion day feels uneventful.
Understanding benefit beyond a response rate
Some patients achieve deep, lasting remissions; others do not respond or later relapse. Results from different diseases, targets, treatment lines and follow-up periods cannot reliably rank products. A complete response on one assessment does not prove that cancer will never return.
Ask which study resembles your situation, what the comparison treatment was and how long patients were followed. Also ask whether results count everyone enrolled, everyone collected or only those actually infused. Being unable to reach infusion is relevant to the real treatment decision.
Three questions for the consultation
- Is the goal a lasting remission, symptom control or a bridge to another treatment?
- Which evidence best matches my diagnosis and treatment history?
- What is the alternative if manufacturing is delayed, disease progresses before infusion or the response is insufficient?
How CAR T differs from stem cell transplantation
Both may involve cell collection, conditioning and specialist care, but their functions differ. CAR T uses engineered T cells to attack a target. Stem cell transplantation rebuilds blood formation after intensive treatment; allogeneic transplantation can also provide a donor immune effect against cancer.
Their roles differ across leukemia, lymphoma and myeloma. Whether to use transplant, CAR T or, in selected circumstances, a sequence involving both depends on the subtype, previous response, alternatives and relapse risk. Ask the team to explain the whole sequence rather than compare procedures in isolation.
Early, late and product-specific risks
Managing complications is part of the treatment itself. Patients need a team able to assess and treat cell-therapy complications promptly, and risks are not identical across products.
Early inflammation and neurological effects
Cytokine release syndrome (CRS) can cause fever, low blood pressure and breathing problems. Immune effector cell-associated neurotoxicity (ICANS) can affect awareness, speech or behavior. Infection and other causes may overlap; symptoms need clinical assessment.
Blood counts, immunity and secondary cancers
Low blood counts, impaired immunity and infection risk can persist beyond early recovery. Secondary malignancies are part of long-term follow-up. Reports of secondary T-cell cancers warrant attention, but do not establish that every reported cancer was caused by CAR T or that every patient will develop one.
Some warnings concern a particular product
In 2025, FDA added a boxed warning for immune effector cell-associated enterocolitis to CARVYKTI. Severe or persistent diarrhea, abdominal pain and weight loss may appear weeks to months after infusion. This specific warning should not be presented as an identical risk for every CAR T product. FDA also concluded that benefit continued to outweigh risk for approved use.
When not to wait for the next visit
Contact the treatment team immediately for fever, breathing difficulty, marked dizziness, changes in awareness or speech, seizures, or severe or persistent diarrhea. Seek emergency care for severe symptoms. Tell clinicians the product and infusion date, and follow the center’s emergency instructions.
Follow-up continues after discharge
Follow-up assesses both cancer response and recovery. Blood counts, infection, immunoglobulins and other checks are individualized. Confirm preventive medicines, vaccinations, driving, work and long-distance travel with the team; one hospital’s timetable is not a universal schedule.
FDA removed REMS requirements for six autologous CAR T products in 2025. That change did not remove serious risks or the need for specialist monitoring and long-term follow-up. Before cross-border treatment, agree who will continue care at home and how findings will reach the treating center.
If disease progresses again
Reassessment considers where disease has progressed, its current characteristics and the previous response. The next step is not automatically another infusion of the same product. The disease and cell-therapy teams should discuss whether new pathology or target testing would change the options.
Estimated total treatment cost
The ranges below cover total medical costs for one CAR-T treatment pathway. Blood-cancer CAR-T products and CT041 have different indications and care requirements; the appropriate option depends on your diagnosis and specialist assessment.
| Treatment plan | Estimated total cost |
|---|---|
| CAR-T for blood cancers | US$176,000–269,000 |
| CT041 (satri-cel) | US$149,000–254,000 |
What’s included
These estimates cover total medical treatment costs, including the CAR-T cell product, specialist consultations and assessment, pretreatment tests, cell collection, conditioning treatment, cell infusion and nursing, necessary hospitalization and monitoring, routine supportive care, and early follow-up tests. Travel and accommodation are not included.
Your individual treatment costs
Your costs depend on the selected product, your condition before treatment, any bridging therapy and your subsequent care needs. Additional treatment, management of complications or extended follow-up may increase the cost. These ranges are indicative only, rather than a fixed package or spending limit. Contact us for a personalized cost estimate based on your medical needs and specialist assessment.
Preparing for an assessment
The aim is to match a particular product to your current treatment stage. Establish medical suitability before confirming a destination, treatment slot or travel plan.
Build a clear treatment timeline
- Pathology and relevant target reports, including the test method, specimen date and full result.
- Previous regimens, dates, best response, progression and serious adverse effects—not just a list of drug names.
- Recent imaging or marrow assessment, blood tests, organ function and infection records, plus previous transplant or cell therapy.
- Current medicines, caregiver and follow-up arrangements. Ask which additional tests are actually needed.
Budget and time should cover the pathway
Ask whether estimates include collection, manufacturing, bridging, conditioning, infusion, hospital care and complications; clarify follow-up and accommodation separately. Manufacturing time, hospital stay and the period required near the center are different questions.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.
- NCI · T-cell transfer therapy
- NCI · CAR T cells: engineering immune cells to treat cancer
- Memorial Sloan Kettering · CAR T-cell patient and caregiver guide
- FDA · CARVYKTI indication and prescribing information
- FDA · CARVYKTI enterocolitis safety update
- NCI · Secondary T-cell cancers after CAR T-cell therapy
- FDA · Removal of REMS for six autologous CAR T-cell products
- CARsgen · Satri-cel approval announcement (manufacturer)
- FDA · Zolbetuximab with chemotherapy in gastric or GEJ cancer
- NCI · Stem cell transplants in cancer treatment
- Cancer Research UK · CAR T-cell therapy